
    
      The study a randomized, double-blinded, placebo-controlled, dose-escalation phase I trial. A
      total of 32 healthy adult subjects will be enrolled into 4 cohorts sequentially. Each
      participant will receive a single IM dose of TNM002 or placebo according to the cohort in
      which they were enrolled. After injection (Day 1), participants remain in the study site for
      observation up to 5 days. Following completion of the safety assessments and sampling for
      PK/PD analyses on Day 4, participants will be discharged from the study site. On Day 8, 15,
      29, 43, 64 and 85, participants will return for safety assessments.
    
  